• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺前毛细血管性肺动脉高压的血流动力学阈值。

Hemodynamic Thresholds for Precapillary Pulmonary Hypertension.

机构信息

Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.

United Therapeutics Corporation, Research Triangle Park, NC.

出版信息

Chest. 2016 Apr;149(4):1061-73. doi: 10.1378/chest.15-0928. Epub 2016 Jan 12.

DOI:10.1378/chest.15-0928
PMID:26501411
Abstract

BACKGROUND

Hemodynamic differentiation between pulmonary arterial hypertension (PAH) and postcapillary pulmonary hypertension (PH) is important because treatment options are strikingly different for the two disease subsets. Whereas patients with PAH can be treated effectively with targeted therapies, their use in postcapillary PH is currently not recommended. Our aim was to establish an algorithm to identify patients who are likely to experience a significant hemodynamic treatment response.

METHODS

We determined hemodynamic cutoffs to discriminate between idiopathic PAH and postcapillary PH in a large database of 4,363 stable patients undergoing first diagnostic right and left heart catheterizations. In a second step, we performed a patient-level pooled analysis of four randomized, placebo-controlled trials including 541 patients with PAH who received treprostinil or placebo, to validate hemodynamic cutoffs with regard to treatment response.

RESULTS

Receiver operating characteristic analysis identified mean pulmonary arterial wedge pressure (mPAWP) < 12 mm Hg and diastolic pulmonary vascular pressure gradient (DPG) ≥ 7 mm Hg as the best hemodynamic discriminators between idiopathic PAH and postcapillary PH. In our treatment study, only patients with mPAWP < 12 mm Hg, DPG > 20 mm Hg or a combination of both had a significant placebo-corrected improvement in hemodynamics.

CONCLUSIONS

mPAWP < 12 mm Hg and DPG > 20 mm Hg identify patients with PAH who are likely to have significant hemodynamic improvement with prostacyclin treatment.

摘要

背景

肺动脉高压(PAH)和毛细血管后性肺动脉高压(PH)的血流动力学区分很重要,因为这两种疾病亚组的治疗选择有显著差异。PAH 患者可以通过靶向治疗有效治疗,而目前不建议将其用于毛细血管后 PH。我们的目的是建立一种算法来识别可能经历显著血流动力学治疗反应的患者。

方法

我们在 4363 例接受首次诊断右心和左心导管检查的稳定患者的大型数据库中确定了血流动力学截止值,以区分特发性 PAH 和毛细血管后 PH。在第二步中,我们对四项包括 541 例接受曲前列尼尔或安慰剂治疗的 PAH 患者的随机、安慰剂对照试验进行了患者水平的汇总分析,以验证血流动力学截止值与治疗反应的关系。

结果

接受者操作特征分析确定平均肺动脉楔压(mPAWP)<12mmHg 和舒张性肺血管压力梯度(DPG)≥7mmHg 是特发性 PAH 和毛细血管后 PH 之间的最佳血流动力学区分指标。在我们的治疗研究中,只有 mPAWP<12mmHg、DPG>20mmHg 或两者兼有患者的血流动力学有显著的安慰剂校正改善。

结论

mPAWP<12mmHg 和 DPG>20mmHg 可识别出可能因前列环素治疗而有显著血流动力学改善的 PAH 患者。

相似文献

1
Hemodynamic Thresholds for Precapillary Pulmonary Hypertension.肺前毛细血管性肺动脉高压的血流动力学阈值。
Chest. 2016 Apr;149(4):1061-73. doi: 10.1378/chest.15-0928. Epub 2016 Jan 12.
2
Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.重度特发性、遗传性或食欲抑制剂相关性肺动脉高压患者目前使用依前列醇的情况:来自法国肺动脉高压注册研究的数据
Int J Cardiol. 2014 Apr 1;172(3):561-7. doi: 10.1016/j.ijcard.2013.12.313. Epub 2014 Jan 22.
3
Clinical Relevance of Fluid Challenge in Patients Evaluated for Pulmonary Hypertension.针对肺动脉高压患者进行液体负荷试验的临床意义
Chest. 2017 Jan;151(1):119-126. doi: 10.1016/j.chest.2016.08.1439. Epub 2016 Aug 26.
4
Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension.肺毛细血管楔压作为肺动脉高压中左心室充盈压相关指标的效用。
J Heart Lung Transplant. 2014 Feb;33(2):157-62. doi: 10.1016/j.healun.2013.10.008. Epub 2013 Oct 11.
5
Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.肺动脉高压患者对静脉内前列环素类似物治疗的反应差异。
Pulm Pharmacol Ther. 2011 Aug;24(4):421-5. doi: 10.1016/j.pupt.2011.01.002. Epub 2011 Jan 18.
6
Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.华法林对皮下注射曲前列尼尔的肺动脉高压患者生存的影响。
Cardiovasc Ther. 2017 Oct;35(5). doi: 10.1111/1755-5922.12281.
7
Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.左心衰竭中肺动脉高压的血流动力学表型分析
Circ Heart Fail. 2017 Sep;10(9). doi: 10.1161/CIRCHEARTFAILURE.117.004082.
8
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.与皮下注射曲前列尼尔治疗的肺动脉高压患者生存改善相关的预后因素:随机、安慰剂对照试验。
J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011. Epub 2011 May 4.
9
Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.13例肺动脉高压患者从静脉注射依前列醇转换为波生坦或西地那非口服治疗后的长期随访
J Heart Lung Transplant. 2007 Apr;26(4):363-9. doi: 10.1016/j.healun.2007.01.022. Epub 2007 Mar 2.
10
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.系统性硬化症患者的临界平均肺动脉压:跨肺压差可预测发生肺动脉高压的风险。
Arthritis Rheum. 2013 Apr;65(4):1074-84. doi: 10.1002/art.37838.

引用本文的文献

1
Risk stratification and treatment goals in pulmonary arterial hypertension.肺动脉高压的风险分层和治疗目标。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01323-2024. Print 2024 Oct.
2
Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications.肺动脉高压的更新临床分类、血流动力学定义及其临床意义
J Cardiovasc Dev Dis. 2024 Feb 27;11(3):78. doi: 10.3390/jcdd11030078.
3
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.
左心疾病相关肺动脉高压的血液动力学表型:一个移动的目标。
Eur Respir J. 2024 Mar 14;63(3). doi: 10.1183/13993003.02280-2023. Print 2024 Mar.
4
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.推进肺动脉高压知识的真实世界证据:现状、挑战与机遇。肺血管研究所创新药物开发倡议真实世界证据工作组的共识声明。
Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct.
5
Implications of Mean Pulmonary Arterial Wedge Pressure Trajectories in Pulmonary Arterial Hypertension.肺动脉楔压轨迹变化对肺动脉高压的影响。
Am J Respir Crit Care Med. 2024 Feb 1;209(3):316-324. doi: 10.1164/rccm.202306-1072OC.
6
Comparison of PCWP and LVEDP Measurements in Patients with Severe Aortic Stenosis Undergoing TAVI-Same Same but Different?经导管主动脉瓣植入术治疗的严重主动脉瓣狭窄患者中肺毛细血管楔压与左心室舒张末期压测量值的比较——相同却又不同?
J Clin Med. 2022 May 25;11(11):2978. doi: 10.3390/jcm11112978.
7
Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) - Protocol of a Multicenter Randomized Control Trial.马昔腾坦联合利奥西呱或马昔腾坦联合司来帕格双重初始联合治疗对肺动脉高压患者血流动力学的影响(SETOUCHI-PH研究)——一项多中心随机对照试验方案
Circ Rep. 2021 Jan 9;3(2):105-109. doi: 10.1253/circrep.CR-20-0133.
8
The haemodynamic assessment of patients with pulmonary arterial hypertension.肺动脉高压患者的血流动力学评估。
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202004. doi: 10.21542/gcsp.2020.4.
9
Role of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: a Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials.预防性补充镁在冠状动脉旁路移植术患者预防术后心房颤动中的作用:20项随机对照试验的系统评价和荟萃分析
J Atr Fibrillation. 2019 Jun 30;12(1):2154. doi: 10.4022/jafib.2154. eCollection 2019 Jun.
10
Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension.肺动脉高压患者左心室充盈压的超声心动图评估
Int J Cardiovasc Imaging. 2019 May;35(5):861-868. doi: 10.1007/s10554-019-01528-6. Epub 2019 Jan 21.